Achillion Deal Looming as Hepatitis Drugs Fail: Real M&A

Achillion Pharmaceuticals Inc., the developer of hepatitis C treatments that was passed over by potential acquirers in the last year, is poised to draw renewed interest after setbacks by rival drugmakers.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.